Neurotransmitter System Changes in 4R-Tauopathies: Cross-Disease Comparison

Neurotransmitter System Changes in 4R-Tauopathies: Cross-Disease Comparison

This page covers neurotransmitter alterations across [PSP](/diseases/progressive-supranuclear-palsy), [CBD](/diseases/corticobasal-degeneration), [AGD](/diseases/argyrophilic-grain-disease), GGT, and [FTDP-17](/diseases/frontotemporal-dementia), including dopaminergic, cholinergic, GABAergic, and serotonergic systems.

The 4R-tauopathies represent a group of neurodegenerative disorders unified by the pathological accumulation of four-repeat tau protein isoforms[@lee2001]. This category includes [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) (GGT), and [Frontotemporal Dementia with Parkinsonism linked to Chromosome 17](/diseases/ftdp-17) (FTDP-17)[@dickson2007]. Despite sharing a common biochemical hallmark—4R tau inclusions—these diseases exhibit distinct clinical phenotypes that correlate with differential patterns of [neurotransmitter](/mechanisms/neurotransmitter-systems) system involvement.

Neurotransmitter System Changes in 4R-Tauopathies: Cross-Disease Comparison

This page covers neurotransmitter alterations across [PSP](/diseases/progressive-supranuclear-palsy), [CBD](/diseases/corticobasal-degeneration), [AGD](/diseases/argyrophilic-grain-disease), GGT, and [FTDP-17](/diseases/frontotemporal-dementia), including dopaminergic, cholinergic, GABAergic, and serotonergic systems.

The 4R-tauopathies represent a group of neurodegenerative disorders unified by the pathological accumulation of four-repeat tau protein isoforms[@lee2001]. This category includes [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) (GGT), and [Frontotemporal Dementia with Parkinsonism linked to Chromosome 17](/diseases/ftdp-17) (FTDP-17)[@dickson2007]. Despite sharing a common biochemical hallmark—4R tau inclusions—these diseases exhibit distinct clinical phenotypes that correlate with differential patterns of [neurotransmitter](/mechanisms/neurotransmitter-systems) system involvement.

Understanding neurotransmitter changes in 4R-tauopathies is critical for several reasons. First, it provides insight into the anatomical substrates underlying the characteristic motor and cognitive symptoms of each disorder. Second, it informs biomarker development, as neurotransmitter metabolites can be measured in cerebrospinal fluid and serve as disease state indicators. Third, it guides therapeutic strategies, as many current treatments target specific neurotransmitter systems[@litvan2011]. This review synthesizes current knowledge on dopaminergic, cholinergic, GABAergic, and serotonergic alterations across 4R-tauopathies, highlighting both shared mechanisms and disease-specific patterns.

Dopaminergic System

Substantia Nigra Pars Compacta Degeneration

The dopaminergic system is prominently affected across all 4R-tauopathies, though the pattern of degeneration varies substantially between diseases[@jellinger1996]. In [PSP](/diseases/progressive-supranuclear-palsy), there is severe loss of dopaminergic neurons in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) (SNc), with an estimated 50-70% reduction in neuronal count at postmortem examination[@hardman1997]. The pattern of neuronal loss in PSP preferentially affects the ventrolateral tier of the SNc, which projects to the [putamen](/brain-regions/putamen)—consistent with the prominent parkinsonian features observed clinically. Neurofibrillary tangles composed of 4R [tau](/proteins/tau-protein) are frequently observed in surviving neurons, and the burden of tau pathology correlates with clinical severity[@braak2003].

CBD demonstrates more variable involvement of the SNc, with some cases showing severe neuronal loss while others preserve relatively normal neuronal populations[@wenning1997]. This heterogeneity aligns with the clinical heterogeneity of CBD, where parkinsonian features may be prominent or minimal. When present, dopaminergic degeneration in CBD tends to be more asymmetric than in PSP, reflecting the contralateral cortical and basal ganglia pathology that characterizes this disorder[@ling2011]. The pattern of neuronal loss in CBD shows a predilection for the dorsal tier of the SNc, which projects to the [caudate nucleus](/brain-regions/caudate-nucleus) rather than the putamen.

In AGD, dopaminergic neuronal loss in the SNc is generally modest compared to PSP and CBD[@togo2002]. While some neuronal loss and tau pathology can be observed, the severity is insufficient to account for the occasional parkinsonian features seen in this condition. The relatively preserved dopaminergic system in AGD contrasts with the prominent memory impairment that characterizes this disorder, suggesting that limbic system dysfunction rather than basal ganglia dysfunction underlies the clinical presentation.

GGT shows variable involvement of the SNc, with the degree of dopaminergic loss depending on the clinical phenotype of the individual case[@martinez2020]. Cases presenting with parkinsonism demonstrate moderate to severe SNc neuronal loss, while those presenting primarily with frontotemporal dementia may have minimal dopaminergic involvement. This heterogeneity reflects the spectrum of clinical presentations in GGT and underscores the importance of considering the underlying clinical phenotype when predicting neurotransmitter system involvement.

FTDP-17 demonstrates variable dopaminergic involvement depending on the specific MAPT mutation[@spina2021]. Certain mutations, such as P301L and G389R, are associated with prominent parkinsonian features and corresponding SNc degeneration, while others present primarily with frontotemporal cognitive features and relatively preserved dopaminergic systems. The correlation between mutation type and phenotype provides insight into the relationship between tau pathology and neurotransmitter dysfunction.

Striatal Dopaminergic Terminals

Beyond neuronal loss in the SNc, 4R-tauopathies demonstrate significant dysfunction in striatal dopaminergic terminals, which can be assessed in vivo using dopamine transporter imaging[@kim2015]. In PSP, there is severe bilateral reduction in striatal dopamine transporter binding, with a characteristic pattern of relatively greater putaminal than caudate involvement—a finding that contrasts with Parkinson's disease where the putamen is more severely affected[@pirker2010]. The "eye-of-the-tiger" pattern on SPECT imaging, showing hot spots of relative preservation in the posterior putamen, has been described in PSP but is not specific to this condition.

CBD demonstrates asymmetric reduction in dopamine transporter binding, corresponding to the clinical asymmetry that characterizes this disorder[@drzezga2008]. The pattern in CBD often shows more severe cortical involvement than in PSP, with reduced binding in the striatum ipsilateral to the more affected cortical hemisphere. This finding supports the hypothesis that cortical-basal ganglia circuits are disrupted in CBD through both cortical and subcortical pathology.

Dopamine transporter imaging in AGD is generally normal or shows only mild changes, consistent with the relatively preserved SNc in this condition[@slawek2013]. This finding can be useful in differentiating AGD from PSP when parkinsonian features are present, as significant dopaminergic dysfunction would favor a diagnosis of PSP or CBD.

Treatment Implications

The dopaminergic dysfunction in 4R-tauopathies has direct therapeutic implications. Levodopa response in PSP is typically limited and transient, with only about 30% of patients demonstrating meaningful improvement, and those who do respond often lose benefit within 1-2 years[@colosimo2003]. This limited response likely reflects the combination of dopaminergic neuron loss and postsynaptic striatal dysfunction, as evidenced by the pattern of imaging abnormalities. In contrast, CBD may show better initial levodopa response, but benefits are also typically not sustained[@valadas2018]. The differential response patterns suggest that while both conditions involve dopaminergic dysfunction, the underlying mechanisms differ in ways that affect treatment responsiveness.

Cholinergic System

Basal Forerain Cholinergic Neurons

The cholinergic system, particularly the basal forebrain cholinergic neurons that project to the cortex and hippocampus, is differentially affected across 4R-tauopathies[@mesulam2013]. In PSP, there is moderate loss of cholinergic neurons in the nucleus basalis of Meynert (NbM), with approximately 30-40% reduction in neuronal count[@liu2015]. This loss correlates with the cognitive impairment that accompanies the motor symptoms in PSP and contributes to the frontal executive dysfunction that is characteristic of the disorder. The pattern of cholinergic loss in PSP is relatively uniform across the rostral-to-caudal extent of the NbM, differing from the gradient observed in [Alzheimer's disease](/diseases/alzheimers-disease).

CBD demonstrates severe loss of basal forebrain cholinergic neurons, often exceeding 50% reduction in neuronal count[@herrero2002]. This severe loss correlates with the prominent cortical cognitive features that characterize CBD, including apraxia, alien limb phenomenon, and executive dysfunction. The asymmetric clinical presentation of CBD is reflected in the cholinergic system, with more severe loss contralateral to the more affected cortical hemisphere[@deutch1986]. Neuropathological studies have demonstrated tau pathology in surviving cholinergic neurons, indicating that the loss is directly related to the disease process rather than secondary to cortical degeneration.

AGD shows relatively preserved basal forebrain cholinergic neurons compared to other 4R-tauopathies[@ferrer2014]. Despite the prominent memory impairment in AGD, the cholinergic system is largely spared, suggesting that the memory dysfunction in this condition is mediated by different mechanisms—likely involving the limbic system pathology with argyrophilic grains affecting entorhinal cortex and hippocampus. This relative preservation may explain why cholinesterase inhibitors, which are effective in Alzheimer's disease, have limited benefit in AGD.

GGT demonstrates variable involvement of the basal forebrain cholinergic system, with more severe loss in cases presenting with cognitive impairment compared to those presenting with parkinsonism[@ahmed2017]. The globular tau inclusions in astrocytes and oligodendrocytes may not directly affect cholinergic neurons to the same degree as the more diffuse neuronal tau pathology seen in other 4R-tauopathies.

FTDP-17 shows mutation-dependent cholinergic involvement, with certain mutations associated with more severe basal forebrain loss[@ghetti2015]. The P301L mutation, which is associated with prominent parkinsonian features, may show intermediate cholinergic loss, while mutations presenting primarily with frontotemporal dementia features may show relatively preserved cholinergic systems.

Cortical Cholinergic Innervation

Beyond loss of cell bodies in the basal forebrain, 4R-tauopathies demonstrate dysfunction in cortical cholinergic terminals[@kuhl2000]. In PSP, there is reduction in cortical choline acetyltransferase (ChAT) activity, particularly in the frontal cortex, which correlates with executive dysfunction. The pattern of cortical cholinergic loss in PSP shows regional variation, with more severe involvement of the prefrontal cortex compared to posterior cortical regions. This regional pattern mirrors the clinical profile of PSP, where executive dysfunction and behavioral changes predominate over memory impairment.

CBD shows severe reduction in cortical ChAT activity across multiple cortical regions, reflecting the extensive cortical pathology in this condition[@cheran2019]. The reduction is more severe than would be predicted from basal forebrain neuronal loss alone, suggesting that there is also local cortical dysfunction affecting cholinergic terminals. This global cortical cholinergic dysfunction contributes to the multifaceted cognitive impairment seen in CBD.

Cholinergic Therapeutics

The cholinergic system represents a therapeutic target in 4R-tauopathies, though response to cholinesterase inhibitors is generally less robust than in Alzheimer's disease[@fabbrini2012]. In PSP, clinical trials of rivastigmine and donepezil have shown modest benefits in some patients, particularly for behavioral symptoms and functional impairment. The response is more variable than in Alzheimer's disease, and not all patients derive benefit. In [CBD](/diseases/corticobasal-degeneration), cholinesterase inhibitors may provide more substantial benefits, particularly for the cognitive and behavioral symptoms, given the more severe cholinergic dysfunction in this condition.

GABAergic System

Cortical GABAergic Neurons

The GABAergic system, comprising the main inhibitory neurotransmitter system in the brain, shows significant alterations across 4R-tauopathies[@rudow2008]. In PSP, there is loss of cortical GABAergic interneurons, particularly parvalbumin-positive and somatostatin-positive subtypes. This loss contributes to the cortical hyperexcitability that has been documented in PSP using transcranial magnetic stimulation studies, which show reduced intracortical inhibition[@cantello2011]. The loss of somatostatin-positive interneurons is particularly notable, as these neurons are specifically vulnerable in PSP and contribute to the executive dysfunction and behavioral changes characteristic of the disorder.

CBD demonstrates severe loss of GABAergic neurons in the motor and premotor cortex, which contributes to the cortical dysfunction that underlies the alien limb phenomenon and apraxia characteristic of this condition[@levy1995]. The loss of GABAergic inhibition in CBD may also contribute to the myoclonus that is occasionally observed in this disorder. Neuropathological studies have demonstrated tau pathology in GABAergic neurons, indicating direct involvement of the inhibitory system in the disease process.

AGD shows relative preservation of cortical GABAergic neurons compared to PSP and CBD[@thal2007]. This preservation may contribute to the relative absence of motor symptoms in AGD, as the GABAergic system plays a critical role in motor control. However, the argyrophilic grain pathology in AGD does involve limbic system structures, and some dysfunction of GABAergic interneurons in the hippocampus may contribute to the memory impairment in this condition.

GGT demonstrates variable involvement of the GABAergic system depending on the regional distribution of pathology[@kovacs2015]. Cases with prominent cortical involvement may show GABAergic neuronal loss, while those with primarily subcortical pathology may preserve cortical GABAergic neurons. The unique astrocytic and oligodendroglial pathology in GGT may have secondary effects on the GABAergic system through disruption of inhibitory circuits.

Subcortical GABAergic Pathways

Beyond cortical involvement, subcortical GABAergic pathways are affected in 4R-tauopathies[@lanciego2012]. In PSP, there is significant loss of GABAergic neurons in the globus pallidus internus (GPi) and externus (GPe), which are critical nodes in the basal ganglia indirect pathway. This loss contributes to the movement disorders in PSP, as the GABAergic output from these nuclei normally inhibits the thalamus and controls movement initiation. The loss of GABAergic neurons in the GPi may paradoxically lead to either increased or decreased thalamic inhibition, depending on the specific pattern of loss.

CBD shows involvement of subcortical GABAergic structures, including the striatum and pallidum[@eidelberg1995]. The asymmetric involvement of these structures contributes to the asymmetric clinical presentation. The loss of striatal GABAergic interneurons, particularly the large aspiny cholinergic neurons that also release GABA, contributes to the disordered movement patterns in CBD.

Therapeutic Implications

The GABAergic system represents a potential therapeutic target in 4R-tauopathies. Benzodiazepines, which enhance GABAergic transmission, are sometimes used to manage rigidity and dystonia in PSP, though their use is limited by sedation and cognitive side effects[@thomas2005]. In [CBD](/diseases/corticobasal-degeneration), GABAergic agents may help manage myoclonus and spasticity. However, chronic use of benzodiazepines is generally not recommended due to the risk of falls, sedation, and potential worsening of cognitive function.

Serotonergic System

Brainstem Serotonergic Nuclei

The serotonergic system, originating from the raphe nuclei in the brainstem, demonstrates distinct patterns of involvement across 4R-tauopathies[@halliday2012]. In PSP, there is significant loss of serotonergic neurons in the dorsal raphe nucleus, with estimates suggesting 40-60% neuronal loss[@halliday1990]. This loss contributes to the depression and sleep disturbances that commonly accompany PSP and may also affect motor function, as the serotonergic system modulates dopaminergic function in the basal ganglia. The severity of serotonergic loss in PSP approaches that seen in Parkinson's disease, which has important implications for understanding the non-motor symptoms in these disorders.

CBD shows variable involvement of the serotonergic system, with some cases demonstrating significant loss while others are relatively preserved[@shin2007]. The heterogeneity likely reflects the variable clinical presentation and pathology distribution in CBD. Cases with more severe brainstem involvement tend to show greater serotonergic loss, which correlates with the presence of depression and other non-motor symptoms.

AGD demonstrates moderate loss of serotonergic neurons in the raphe nuclei[@resende2018]. This loss may contribute to the mood symptoms that can accompany AGD, though depression is less commonly reported in this condition compared to PSP. The serotonergic loss in AGD is less severe than in PSP, which may reflect the more limited brainstem involvement in AGD compared to other 4R-tauopathies.

GGT shows variable serotonergic involvement depending on the specific clinical phenotype[@bigio2020]. Cases with prominent brainstem pathology demonstrate more severe serotonergic loss, while those with primarily cortical or subcortical involvement may show relative preservation.

FTDP-17 shows mutation-dependent serotonergic involvement, with certain MAPT mutations associated with more severe brainstem pathology and corresponding serotonergic loss[@hutton2003]. The P301L mutation, which is associated with prominent subcortical pathology, often demonstrates significant serotonergic dysfunction.

Cortical Serotonergic Terminals

Beyond loss of cell bodies in the raphe nuclei, 4R-tauopathies demonstrate dysfunction in cortical serotonergic terminals[@politis2015]. In PSP, there is reduction in cortical serotonin transporter binding, which can be visualized using SPECT imaging. This reduction correlates with the severity of depression and may contribute to the cognitive dysfunction in PSP, as serotonin plays an important role in executive function and working memory.

CBD demonstrates variable cortical serotonergic dysfunction, with more severe involvement in cases with prominent mood symptoms[@cantor2021]. The asymmetric clinical presentation in CBD may be reflected in asymmetric cortical serotonergic dysfunction, though this has not been thoroughly investigated.

Therapeutic Implications

The serotonergic system has important therapeutic implications in 4R-tauopathies. Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat depression in these conditions, though response may be less robust than in primary depression due to the underlying neurodegenerative process[@friedman2014]. The serotonergic system also modulates motor function, and SSRIs may have modest beneficial effects on parkinsonian symptoms in some patients, likely through enhancement of serotonergic-dopaminergic interactions. In [PSP](/diseases/progressive-supranuclear-palsy), the significant serotonergic loss may contribute to treatment resistance.

Cross-Disease Comparison Matrix

| Neurotransmitter System | PSP | CBD | AGD | GGT | FTDP-17 |
|-------------------------|-----|-----|-----|-----|---------|
| Dopaminergic (SNc) | Severe (50-70%) | Variable, asymmetric | Mild | Variable | Mutation-dependent |
| Dopaminergic (Striatum) | Severe, bilateral | Asymmetric | Normal | Variable | Variable |
| Cholinergic (Basal Forebrain) | Moderate (30-40%) | Severe (>50%) | Preserved | Variable | Mutation-dependent |
| Cholinergic (Cortex) | Moderate reduction | Severe reduction | Preserved | Variable | Variable |
| GABAergic (Cortex) | Moderate loss | Severe loss | Preserved | Variable | Variable |
| GABAergic (Subcortical) | GPi/GPe loss | Striatal involvement | Minimal | Variable | Variable |
| Serotonergic (Raphe) | Severe (40-60%) | Variable | Moderate | Variable | Mutation-dependent |
| Serotonergic (Cortex) | Reduced SERT | Variable | Reduced | Variable | Variable |

Therapeutic Implications

Current Treatment Approaches

The neurotransmitter changes in 4R-tauopathies have direct implications for current treatment approaches[@stamelou2018]. For dopaminergic symptoms, levodopa remains the mainstay of treatment, though response is typically limited in PSP and variable in CBD. The standard dose is 300-1000 mg/day of levodopa, divided into three to four doses. Early initiation may provide better response, but benefits often diminish within 1-2 years. Dopamine agonists such as pramipexole and ropinirole may be added, though their efficacy in 4R-tauopathies is modest.

For cognitive and behavioral symptoms, cholinesterase inhibitors such as donepezil (5-10 mg/day), rivastigmine (3-12 mg/day), and galantamine (8-24 mg/day) may provide modest benefits, particularly in CBD where cholinergic loss is severe[@litvan2019]. Response is less robust than in Alzheimer's disease, and benefits may be limited to specific symptom domains. The 5-HT3 antagonist mefloquine has been investigated in PSP but did not show efficacy in clinical trials.

For mood symptoms, SSRIs such as sertraline (50-200 mg/day), escitalopram (10-20 mg/day), and citalopram (20-40 mg/day) are commonly used[@schrag2020]. Response may be less robust than in primary depression due to the neurodegenerative component. Second-line agents include mirtazapine (15-45 mg/day) and bupropion (150-300 mg/day).

Emerging Therapeutic Strategies

Several emerging therapeutic strategies target neurotransmitter systems in 4R-tauopathies[@boxer2020]. Neuroprotective approaches aim to preserve remaining neurons, with compounds such as davunetide (a nasally administered peptide) showing promise in clinical trials. Gene therapy approaches target neurotrophic factors such as BDNF and GDNF to support surviving neurons. Deep brain stimulation of the GPi or STN has been used in select cases of PSP and CBD, with variable results.

Conclusion

The neurotransmitter systems in 4R-tauopathies demonstrate distinct patterns of involvement that correlate with the clinical phenotypes of each disorder. PSP is characterized by severe dopaminergic and serotonergic loss with moderate cholinergic and GABAergic involvement, explaining the prominent parkinsonian features, depression, and cognitive dysfunction. CBD shows severe cholinergic and variable dopaminergic loss, with significant cortical involvement reflecting the multifocal clinical presentation. AGD demonstrates relatively preserved neurotransmitter systems, consistent with its primary presentation as a memory disorder with minimal motor features. GGT and FTDP-17 show variable patterns that depend on clinical phenotype and specific genetic mutation, respectively.

Understanding these neurotransmitter changes informs both diagnostic evaluation and therapeutic decision-making. While current treatments are largely symptomatic and provide limited benefit, a thorough understanding of the underlying neurochemical dysfunction provides a foundation for developing disease-modifying therapies that target the specific mechanisms of neurotransmitter loss in each 4R-tauopathy.

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)
• [FTDP-17](/diseases/frontotemporal-dementia)
• [Tauopathies Overview](/mechanisms/tauopathies)
• Neuroimmune Response in 4R-Tauopathies
• Dopamine Signaling in Neurodegeneration
• Acetylcholine Signaling in Neurodegeneration

References